Skip to content
Press release Regulatory

Nanoform financial calendar for 2023

Company Announcement

Nanoform Finland Plc

December 7th, 2022

11.00 a.m. Finnish time / 10.00 a.m. Swedish time

Nanoform financial calendar for 2023

Helsinki, Finland – In this company announcement Nanoform provides its financial calendar for 2023, which include the planned publication dates of its financial reports, Annual Report and Annual General Meeting.

Planned publication dates for Nanoform’s financial reports:

  • report for Q4 2022 and full year 2022: February 28th, 2023
  • report for Q1 2023: May 25th, 2023
  • report for Q2 2023 and half-year 2023: August 24th, 2023
  • report for Q3 2023 and January-September 2023: November 22nd, 2023
  • report for Q4 2023 and full year 2023: February 29th, 2024

Nanoform plans to publish its Annual Report for the year 2022, which includes the review by the Board of Directors and the audited annual accounts, latest end of March 2023.

Nanoform’s Annual General Meeting 2023 is planned to be held on April 12th, 2023.

Nanoform would also like to inform that Nanoform management will present to investors at DNB Nordic Healthcare Conference in Oslo December 15th (2022) and SEB Nordic Seminar in Copenhagen January 9th (2023). Additionally, Nanoform will host an Analyst Day (sell side) at its headquarters in Helsinki January 18th (2023), registration requests are welcome to the following e-mail:

For further information, please contact:

Albert Hæggström, CFO / +358 29 370 0150

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations / +46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its Nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit